WASHINGTON TRUST Co lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 180,732 shares of the company’s stock after purchasing an additional 5,358 shares during the period. Johnson & Johnson accounts for 1.1% of WASHINGTON TRUST Co’s investment portfolio, making the stock its 24th biggest holding. WASHINGTON TRUST Co’s holdings in Johnson & Johnson were worth $23,699,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Houlihan Financial Resource Group Ltd. purchased a new position in Johnson & Johnson in the 4th quarter valued at approximately $1,376,000. Bowen Hanes & Co. Inc. grew its stake in Johnson & Johnson by 11.5% in the 4th quarter. Bowen Hanes & Co. Inc. now owns 362,432 shares of the company’s stock valued at $52,868,000 after buying an additional 37,290 shares in the last quarter. Community Financial Services Group LLC grew its stake in Johnson & Johnson by 2.6% in the 4th quarter. Community Financial Services Group LLC now owns 25,571 shares of the company’s stock valued at $3,730,000 after buying an additional 645 shares in the last quarter. Chelsea Counsel Co. grew its stake in Johnson & Johnson by 3.9% in the 4th quarter. Chelsea Counsel Co. now owns 45,344 shares of the company’s stock valued at $6,614,000 after buying an additional 1,693 shares in the last quarter. Finally, Csenge Advisory Group grew its stake in Johnson & Johnson by 18.7% in the 4th quarter. Csenge Advisory Group now owns 13,480 shares of the company’s stock valued at $1,966,000 after buying an additional 2,127 shares in the last quarter. Institutional investors own 67.66% of the company’s stock.

NYSE JNJ opened at $144.37 on Friday. Johnson & Johnson has a 52-week low of $109.16 and a 52-week high of $157.00. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.05 and a current ratio of 1.31. The company has a market capitalization of $386.52 billion, a P/E ratio of 19.10, a P/E/G ratio of 3.19 and a beta of 0.71. The company has a fifty day moving average of $146.81 and a 200-day moving average of $142.30.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.03 by $0.27. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The company had revenue of $20.69 billion during the quarter, compared to the consensus estimate of $19.48 billion. During the same period in the previous year, the firm posted $2.10 EPS. The firm’s revenue was up 3.3% compared to the same quarter last year. As a group, analysts forecast that Johnson & Johnson will post 7.68 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a dividend of $1.01 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.95. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.80%. The ex-dividend date is Friday, May 22nd. Johnson & Johnson’s payout ratio is currently 43.78%.

A number of research analysts recently weighed in on JNJ shares. Argus reiterated a “buy” rating and issued a $155.00 price objective (down from $165.00) on shares of Johnson & Johnson in a research note on Friday, March 27th. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $160.00 to $170.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. SVB Leerink cut their price target on shares of Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating for the company in a report on Wednesday, April 8th. Credit Suisse Group reissued a “buy” rating and issued a $161.00 price target on shares of Johnson & Johnson in a report on Tuesday, April 28th. Finally, Wells Fargo & Co raised shares of Johnson & Johnson to a “hold” rating in a report on Wednesday, April 22nd. Four investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $163.47.

In other Johnson & Johnson news, Director William D. Perez purchased 500 shares of the stock in a transaction on Friday, March 13th. The stock was acquired at an average cost of $127.69 per share, with a total value of $63,845.00. Following the completion of the purchase, the director now directly owns 16,030 shares of the company’s stock, valued at approximately $2,046,870.70. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.27% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Treasury Bonds

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.